Previous Article in Journal
Structural Characterization and Anticoagulant Potential of Colochirus quadrangularis Fucosylated Glycosaminoglycan 5−12 Oligomers with Unusual Branches
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium

by
Fan Zhang
1,2,*,
Wenhui Wang
1,
Doug R. Braun
2,
Gene E. Ananiev
3,
Weiting Liao
1,
Mary Kay Harper
4,
Scott R. Rajski
2 and
Tim S. Bugni
2
1
Department of Pulmonary and Critical Care Medicine, Zhongnan Hospital of Wuhan University, TaiKang Center for Life and Medical Sciences, School of Pharmaceutical Sciences, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University, Wuhan 430071, China
2
Pharmaceutical Sciences Division, University of Wisconsin–Madison, Madison, WI 53705, USA
3
Small Molecule Screening & Synthesis Facility, UW Carbone Cancer Center, Madison, WI 53705, USA
4
Department of Medicinal Chemistry, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
*
Author to whom correspondence should be addressed.
Mar. Drugs 2025, 23(2), 65; https://doi.org/10.3390/md23020065 (registering DOI)
Submission received: 15 January 2025 / Revised: 31 January 2025 / Accepted: 1 February 2025 / Published: 3 February 2025
(This article belongs to the Section Structural Studies on Marine Natural Products)

Abstract

:
The discovery of new natural products remains a cornerstone of therapeutic innovation, and effective analytical tools for rapid dereplication can significantly accelerate this process. Using Isotopic Fine Structure (IFS) mass spectrometry, we rapidly identified three new dimeric benzofluorene glycosides, lomaiviticins F–H (13), from a marine-derived Micromonospora sp. bacterium. These compounds were isolated and structurally elucidated through advanced spectroscopic techniques, including FT-ICR-MS and NMR. Lomaiviticins F–H exhibit unique structural features, notably the 4-O-methyl-l-angolosamine moieties, which differentiate them from previously known lomaiviticins A–E. The discovery of these compounds highlights distinct biosynthetic linkages within the lomaiviticin family, particularly the C2–C2′ conjoining bonds characteristic of the dimers. Compounds 13 were evaluated for in vitro cytotoxicity against a panel of human cancer cell lines; the resulting IC50 values confirmed that the dimeric diazofluorenes of lomaiviticins A and B are critical for anticancer activity. These findings emphasize the utility of IFS in expediting natural product discovery while providing valuable insights into structural and functional characterizations of bioactive compounds.

Graphical Abstract

1. Introduction

Lomaiviticins represent a unique class of natural products derived from marine actinomycetes that have captivated researchers due to their potent anticancer activities [1,2,3,4,5]. Structurally, these complex diazofluorene dimers are distinguished by their symmetric or pseudosymmetric architecture, wherein two halves of the molecule are connected by a sterically hindered C–C bond and adorned with 2–4 unique glycosylated sugars (Figure 1). First isolated in 2001, lomaiviticins A and B quickly became notable for their exceptional bioactivities [1], and subsequent efforts led to the discovery of lomaiviticins C–E in 2012 [2] (Figure 1). Recent microED studies have refined the structural understanding of lomaiviticin C, revising the orientation of the cyclohexenone ring and secondary glycoside configuration in lomaiviticins [6]. Biosynthetically, lomaiviticins share a lineage with kinamycins [7,8,9,10,11,12,13,14] (Figure 1), another class of diazofluorene-containing natural products. However, while kinamycins are sourced from terrestrial Streptomyces species [7,8,9,10,11], lomaiviticins originate from marine actinomycetes such as Micromonospora lomaivitiensis and Salinispora species [1,2,15,16]. A distinguishing biosynthetic hallmark of lomaiviticins is the dimerization of the diazofluorene core, which was proposed to be catalyzed by homologs of ActVA-orf4, such as Lom19 in Salinispora pacifica [15] and Strop2191 in Salinispora tropica [16]. This unique dimerization significantly contributes to their enhanced bioactivity. Functionally, lomaiviticins A and B are remarkable for their ability to induce double-strand DNA breaks through mechanisms involving vinyl radical intermediates, leveraging their dual diazofluorene moieties to coordinate efficient DNA backbone scission [17]. In contrast, the mono-diazofluorene lomaiviticins C–E lack this robust DNA-damaging capability and exhibit comparatively lower cytotoxicity. The rarity of lomaiviticins in nature, coupled with the challenges of their total synthesis, offers unique opportunities for the discovery of new analogs through both natural product exploration and innovative synthetic methodologies.
While a range of HRMS-based tools has accelerated the discovery of new natural products, dereplication using HRMS data remains challenging, as accurate mass alone is often insufficient to reliably determine a molecular formula. Recently, we demonstrated the utility of IFS analysis as a powerful approach for determining the exact molecular formulas of natural products [18,19]. IFS holds significant promise for improving the accuracy of dereplication strategies, even when working with crude extracts. The ultrahigh resolving power of FT-ICR-MS enabled the determination of exact molecular formulas of the three intriguing molecules from the crude extract of WMMC-274, leading to the discovery of three new dimeric benzofluorene glycosides, lomaiviticins F–H (13) (Figure 2). Here, we describe the isolation, structure elucidation and biological evaluation for 13.

2. Results and Discussion

2.1. IFS-Based Dereplication

Although HR-ESI-LCMS provides rapid insight into potentially interesting molecules, most LCMS data do not provide adequate information for dereplication. Dereplication often proceeds by comparing the accurate mass data (error < 5 ppm) with those of known compounds in a given database. Unambiguous assignment of elemental composition facilitates accurate dereplication and is a critical step en route to the structure determination of unknown compounds. Unfortunately, the correct formula cannot be determined solely on the basis of mass accuracy for monoisotopic peaks [20]. IFS, observed by ultrahigh-resolution FT-ICR-MS, is a unique mass spectral signature resulting from different mass defects of isotopic contributions and their natural abundances. In our previous study, we demonstrated the feasibility of this approach to determine the exact molecular formula of forazoline A; the realization that IFS-generated data differed from that originally published inspired our unambiguous structural revision for forazoline A [18]. It is noteworthy that applications of IFS data are generally limited to pure compounds. However, we have also directly applied FT-ICR-MS to analyses of crude extracts, and as seen here, IFS enabled the determination of the exact molecular formulas of 13 from the crude exact of WMMC-274 (Figure 3). The exact molecular formulae were effectively utilized in dereplication, significantly streamlining our decision-making process to prioritize molecules from WMMC-274 among a vast array of marine actinomycetes. Notably, 13, prioritized with the aid of IFS data, proved to be new lomaiviticins on the basis of database queries (Antibase and Scifinder).

2.2. Structure Elucidation

The molecular formula of lomaiviticin F (1) was established as C57H64N2O17 based on FT-ICR-MS data of the crude extract sample of WMMC-274 (Figure 3b), and HR-ESI-MS was carried out on the pure compound to confirm that the isolated vs. crude molecules detected were identical (Figure S7). Analysis of the 1H and 13C NMR spectra for 1 (Table 1) in CD3OD revealed the presence of 31 protons and 29 carbons, which accounted for less than half of the protons and close to half of the carbons in the molecular formula of 1, suggesting that 1 was likely a symmetric dimer. The NMR spectroscopic features, including 2 aromatic protons (δH 6.74 and 6.58, J = 9.1 Hz) and 10 aromatic carbons (δC 186.2, 184.9, 157.0, 156.5, 128.0, 126.0, 125.8, 123.4, 118.1, 117.1), were characteristic of a 5,8-dihydroxy-1,4-naphthoquinone substructure. HMBC correlations from H-4 to C-2, C-3, C-4a and C-11b, from H-2 to C-1, C-3, C-4 and C-11b, together with the HMBC correlations from H2-12 to C-2, C-3 and C-13, established the other key substructure of the cyclohexanone ring. HMBC correlations from H-5 to C-4a, C-5a, C-6, C-11, C-11a and C-11b indicated that C-5 was attached to C-4a and C-5a. Similarly to lomaiviticin C, we did not observe an HMBC correlation from H-4 to C-5 using a nJC,H threshold of 8 Hz, and a COSY correlation between H-2 and H-4 was observed [6], which completed the orientation of the cyclohexanone substructure with respect to the five membered ring system. We assigned a C-4 linked methoxy group on the basis of the HMBC correlations from H3-4-OMe to C-4. The COSY NMR data for 1 showed a series of correlations establishing the sugar moiety H-14–H3-19. The placements of the N,N-dimethylamino and methoxy group at C-16 and C-17 were revealed by HMBC correlations from H3-21 and H3-22 to C-16, and from H3-20 to C-17, respectively. In turn, HMBC correlations from H-14 to C-3 indicated that the sugar moiety was connected to C-3. There were three exchangeable protons attached to three oxygenated aromatic carbons (C-7, C-10 and C-11), which were assigned as 7-OH, 10-OH and 11-OH to complete the monomer structure of 1. While a molecular formula of C29H34NO9 accounted for the monomer as interpreted by 1D and 2D NMR, obviously, due to the symmetry of compound 1, the molecular formula C57H64N2O17 proposed early on was likely the in-source fragment of the actual molecular formula C58H68N2O18. We postulated that the methoxy group was easily lost under MS conditions, causing the observed mass data to be m/z 32 less than the parent ion; this theory was further confirmed by ESI MS/MS data for compound 1 (Figure S8). Analysis of the MS/MS of 1 revealed mass fragments with differences in m/z 32 (lost CH4O) and m/z 189 (accounting for one sugar unit) from the parent ion. Ultimately, the two identical monomer units were established as being linked to each other by a C–C bond involving C-2 and C-2′ on the basis of HMBC correlations from H-2 to C-2′.
The relative configuration of 1 was determined using a combination of ROESY data (Figure 4) and coupling constants. ROESY correlations from H-2 (2′) to H3-13 (13′) indicated their coplanarity within the cyclohexanone ring system. Furthermore, both H-2 and H-4 were observed as singlets in the 1H spectrum, consistent with the singlets observed for H-2 (2′) and H-4 (4′) in lomaiviticin C, indicating that H-2 (2′) and H-4 (4′) have the same relative configuration as in lomaiviticin C. Hence, the relative configurations of C-2 (2′), C-3 (3′), and C-4 (4′) were assigned as being identical compared to the known lomaiviticins. In the two-amino-sugar unit attached to C-3 and C-3′, the anomeric proton H-14 (14′) was assigned to be in an α-configuration based on the small coupling constant (J = 2.6 Hz) between H-14 (14′) and H2-15 (15′). The large coupling constants between H-16 (16′) and H-17 (17′) (J = 9.4 Hz), and between H-17 (17′) and H-18 (18′) (J = 9.4 Hz) implied that all three protons H-16 (16′), H-17 (17′) and H-18 (18′) were in the axial position, consistent with the ROESY correlations from H-16 (16′) to H-18 (18′) and from H-17 (17′) to the N-CH3 groups at C-16 (16′); these data established the sugar residues of 1 as α-4-O-methyl-angolosamine. 4-O-methyl-angolosamine, containing a dimethylamino group, has also been found in negestatins A and B [21,22], which have the same benzofluorene core. The absolute configuration of 4-O-methyl-angolosamine in negestatin A was tentatively assigned as 4-O-methyl-l-angolosamine given the presence of a 3,5-epimerase in the biosynthetic pathway for negestatin A [21]. The absolute configuration of α-4-O-methyl-angolosamine in 1 was also determined as l on the basis of optical rotation data for acid hydrolysates of 1 [2,23]. The absolute configuration of the aglycone core of 1 was deduced to be the same as (−)-lomaiviticins A–E on the basis of the large negative optical rotation we observed for 1, while the optical rotation values for (−)-lomaiviticins A–E have all been reported as negative [1,2].
IFS (Figure 3c) of lomaiviticin G (2) established its molecular formula as C56H62N2O17, and the pure compound was further confirmed by HR-ESI-MS (Figure S20). The 1H and 13C NMR data of 2 (Table 2) showed many similarities to those of 1. However, 56 protons were observed for compound 2 in the 1H NMR spectrum, especially the presence of six aromatic protons, suggesting that the two putative monomer units in 2 were not identical. Comparisons of the NMR data for 2 with those of 1 revealed the presence of 5,8-dihydroxy-1,4-naphthoquinone and cyclopentadiene substructures, along with the same sugar moieties found in 1 (4-O-methyl-angolosamine). However, significantly different structural features were found for the cyclohexanone ring systems in 2. The 13C-13C COSY of 13C-labeled lomaiviticin G (Table S19) generated by fermentation using uniformly labeled 13C glucose quickly established the carbon–carbon connectivity of the remaining substructures. Finally, HMBC correlations from H-2 to C-2′ again showcased the importance of C-2 and C-2′ in constituting the dimer-forming C–C linkage. Meanwhile, the 13C-13C COSY correlations between C-2 and C-2′ further supported that the two units are connected through the C2–C2′ bond. ROESY correlations between H-2 (2′) and H3-13 (13′) confirmed their coplanarity within the cyclohexanone ring system, consistent with the corresponding correlations observed in compound 1. Furthermore, a comparative analysis of the 1H and 13C NMR NMR data revealed that the configurations of the α-4-O-methyl-angolosamine residues in compound 2 matched those in compound 1. From a biosynthetic perspective, the absolute configuration of compound 2 around the cyclohexanone ring and the sugar moieties was envisioned to be identical to that found in 1; this was confirmed by the negative optical rotation value generated with 2, as had also been the case with compound 1.
IFS (Figure 3d) of lomaiviticin H (3) indicated the molecular formula of 3 as C72H92N6O22. Although compound 3 (Table 3) bore some structural similarity to 1 in terms of the 1H and 13C NMR data, it became apparent early on that 3, unlike 1, was not a symmetric dimer. NMR data comparisons revealed that the two methoxy groups attached to C-4 and C-4′ in 1 were each replaced by amino sugar moieties in compound 3. In addition, COSY data made the presence of the spin systems H-23–H3-28 (H-23′–H3-28′) clear. Accordingly, N,N-dimethylamino groups were located at C-26 (26′) as indicated by clear HMBC correlations from H3-29 (29′) and H3-30 (30′) to C-26 (26′). Interestingly, although the four amino sugar moieties accounted for four nitrogen atoms, there remained two nitrogen atoms unaccounted for. The shielded chemical shift for C-5 (δC 77.9), combined with the clear presence of only one cyclopentadienyl proton (H-5′), suggested that lomaiviticin H contained a diazo group at C-5; comparisons with spectroscopic data for previously reported lomaiviticins A–E supported the assignment of a diazo moiety at C-5 of 3.
The 13C NMR chemical shifts of 4-O-methyl-angolosamine in 3 were almost identical to those of 1 and 2, suggesting that these sugar units had the same α-l configuration as those in 1. The relative configuration of the other sugar units attached to C-4 and C-4′ were determined by ROESY data and coupling constants. The large coupling constant (10 Hz) observed for H-23 (H-23′), the large coupling constant (10 Hz) between H-25 and H-26, and the large coupling constant (10 Hz) between H-26 and H-27 indicated that protons H-23, H-25, H-26 and H-27 were all in axial positions, allowing us to confidently assign the remaining sugar moieties attached to C-4 and C-4′ of 3 as β-N,N-dimethyl-pyrrolosamine. The absolute configuration of β-N,N-dimethyl-pyrrolosamine was assigned as l based upon optical rotation analyses of the TFA hydrolysis product, which shared the same stereochemistry as pyrrolosamine in lomaiviticins A–E [1,2]. The aglycone and 4-O-methyl-angolosamine moieties of compound 3 were found to have the same relative configuration as those of compound 1, based on the analysis of ROESY correlations and 1H-1H coupling constants, followed by circular dichroism (CD) spectral (Figure S30) and optical rotation analysis. Consequently, compound 3 was deduced to be (−)-lomaiviticin H.

2.3. Biological Activity

Lomaiviticins are potent antiproliferative and antimicrobial agents, and it has been demonstrated that the dimeric diazofluorene structure is critical to bioactivity [17]. Lomaiviticin A showed cytotoxicity with IC50 values ranging from 0.01 to 98 ng/mL (LNCaP: 2 nM; K562: 11 nM; HCT-116: 2 nM; HeLa: 7 nM) [1,2], and induces double-strand breaks (DSBs) in DNA by a mode of association involving the penetration of both diazofluorene residues into the duplex. The related analogs lomaiviticins C–E, which only contain one or no diazo functional group, do not induce DNA DSBs, implying that DSBs result from two proximal DNA backbone cleaving events, each of which is triggered by diazofluorene-dependent radical chemistry. Predicated on this knowledge, we hypothesized that lomaiviticins F–H, lacking the two diazo functional groups, would be much less toxic against cancer cell lines than lomaiviticin A. Given this hypothesis, we evaluated the cytotoxicity of 13 against seven cell lines (Table 4). As predicted, the IC50 values of lomaiviticins F–H proved significantly higher than those previously noted for lomaiviticin A, thus supporting the notion that the dual diazofluorene moieties in lomaiviticins A and B are vital to cytotoxicity.
Although lomaiviticins F–H exhibit structural differences, their cytotoxic activities remain similarly weak, indicating that these modifications do not lead to a substantial enhancement in biological activity. Notably, lomaiviticin H (3), which retains a single diazo functional group, does not demonstrate any significant increase in potency over the other two analogs, further emphasizing that both diazofluorene groups are required to maintain potent cytotoxicity. The drastic reduction in activity observed for lomaiviticins F–H highlights the functional importance of these structural features and suggests that their loss significantly diminishes the ability to engage DNA or trigger cytotoxic mechanisms.

3. Conclusions

We employed IFS to facilitate the confirmation of new molecules directly from crude/semi-crude extracts, representing a streamlined approach for rapid and accurate dereplication that can also be linked to bioactivity. Lomaiviticins F–H are structurally most related to the previously known lomaiviticins A–E, and nenestatin B [22] (Figure 1). Specifically, lomaiviticins F–H contain 4-O-methyl-L-angolosamine moieties, attached to C-3 and C-3′, which is the same aminosugar unit present in nenestatin B, whereas lomaiviticins A–E bear an oleandrose unit at these positions. Additionally, the location of the bridging bonds between the monomers in nenestatin B and lomaiviticina A–E are distinct. Nenestatin B is characterized as a C2–C1′ asymmetric heterodimer, while lomaiviticins A–E are C2–C2′ dimers. Interestingly, lomaiviticins F–H share the same C-2/C2′ conjoining bond between the monomeric units as lomaiviticins A–E. The discovery of lomaiviticins F–H enriches the chemical diversity of the lomaiviticin family, indicates a close biosynthetic relationship between these two classes lomaiviticins and nenestatins, and provides further insight into the dimerization mechanisms for both families. Finally, cytotoxicity data for lomaiviticins F–H confirm the importance of the diazofluorene moiety in lomaiviticins expressing meaningful anticancer activities; the presence of two diazofluorene moieties appears to be essential for lomaiviticins to exhibit cytotoxicity, supporting the induction of DNA double-strand breaks as a primary mechanism of action for this class of natural products.

4. Materials and Methods

4.1. General Experimental Procedures

Optical rotations were measured on a Perkin–Elmer 241 Polarimeter (Shelton, CT, USA). UV spectra were recorded on an Aminco/OLIS UV-Vis Spectrophotometer (Bogart, GA, USA). CD spectra were recorded using an AVIV Model 420 Circular Dichroism Spectrometer (Lakewood, NJ, USA). IR spectra were measured with a Bruker Equinox 55/S FT–IR Spectrophotometer (Santa Barbara, CA, USA). Both 1D and 2D NMR spectra were obtained using a Bruker Avance 500 MHz spectrometer with 1H{13C/15N} cryoprobe and 500 MHz spectrometer with 13C/15N{1H} cryoprobe (Billerica, MA, USA); chemical shifts were referenced to the residual solvent peaks (CD3OD: δH = 3.31, δC = 49.15). HRMS and MSMS data were acquired with a Bruker MaXis 4G QTOF mass spectrometer (Billerica, MA, USA). FT-ICR-MS and MSMS were performed on a 12-T solariX XR (Bruker, Bremen, Germany) and FT-ICR mass spectrometer equipped with a nano-electrospray ionization source. RP HPLC was performed using a Shimadzu Prominence HPLC system and a Phenomenex Luna C18 column (250 × 10 mm, 5 µm) (Torrance, CA, USA).

4.2. Biological Material

WMMC-274 was isolated from sponge Suberites sp. which were collected on August 7, 2013, near Stan Blum State Park boat launch (27°28′45.7″ N, 80°18′42.8″ W) in Florida, USA. The sponge specimen was taxonomically identified by Mary Kay Harper (University of Utah, Salt Lake City, UT, USA). A voucher specimen is housed at the University of Wisconsin-Madison. For cultivation, sponge samples (1 cm3) were ground in 500 μL sterile seawater and then diluted by the addition of 500 μL sterile seawater. Subsequently, 400 μL of diluted sponge sample was added to 200 μL of sterile seawater and 100 μL was plated using a sterile L-shaped spreader. Dilutions were separately plated on six media supplemented with artificial seawater: ISP2, R2A, ISP3, Gauze 1, HV, and Bonito [24,25,26,27,28]. Each medium was supplemented with 50 μg/mL cycloheximide, 25 μg/mL nystatin, and 25 μg/mL nalidixic acid. HV medium was additionally supplemented with 25 μg/mL gentamicin. The plates were incubated at 28 °C and colonies were isolated over the course of two months. Strain WMMC-274 was purified from an HV medium isolation plate [24].
Sequencing: 16S rDNA was sequenced as previously described [29]. WMMC-274 was identified as Micromonospora sp., and its genome was deposited to GenBank and assigned the accession number KY015097.1.
Fermentation, extraction, and isolation: Three 10 mL seed cultures (25 × 150 mm tubes) in medium ASW-A (20 g soluble starch, 10 g glucose, 5 g peptone, 5 g yeast extract, 5 g CaCO3 per liter of artificial seawater) were inoculated with strain WMMC-274 and agitated at 200 RPM for 14 d at 28 °C. To make artificial seawater, solution I (415.2 g NaCl, 69.54 g Na2SO4, 11.74 g KCl, 3.40 g NaHCO3, 1.7 g KBr, 0.45 g H3BO3, 0.054 g NaF) and II (187.9 g MgCl2•6H2O, 22.72 g CaCl2•2H2O, 0.428 SrCl2•6H2O) were made up separately, and combined to give a total volume of 20 L. Two-liter flasks (6 × 500 mL) containing ASW-A medium with Diaion HP20 (7% by weight) were inoculated with 10 mL from the culture tube and shaken at 200 rpm at 28 °C for 14 days. Filtered HP20 was washed with distilled H2O and extracted with acetone. The acetone extract (8 g) was subjected to a liquid–liquid partitioning using 30% aqueous CH3OH and CHCl3 (1:1). The CHCl3-soluble partition (0.7 g) was fractionated by Sephadex LH20 column chromatography (CHCl3:CH3OH, 1:1). The fractions containing 1 and 2 were further subjected to RP HPLC (40–70% CH3OH-H2O with H2O over 30 min, 4.0 mg/mL) using a Phenomenex Luna C18 column (250 × 10 mm, 5 µm), yielding 1 (10.5 mg, tR 17.1 min) and 2 (9 mg, tR 19.6 min). The fractions containing 3 were further subjected to RP HPLC (10–80% CH3CN-H2O with H2O containing 0.05% trifluoroacetic acid over 24 min, 4.0 mg/mL) using a Phenomenex Luna C18 column (250 × 10 mm, 5 µm), and phosphate buffer (pH = 7) was added to the fraction-collecting tubes before the fraction collection to maintain a stable pH. Collecting tubes that contained compound 3 were then combined and further diluted with water (four times the collection fraction volume) and loaded to a benchtop C18 column to remove salts; a column wash with 100% CH3CN afforded pure 3 (14.6 mg, tR 18.8 min).
Lomaiviticin F (1): red power; [α]25D −225 (c 0.2, CH3OH); UV (CH3OH) λmax (log ε) 205 (3.85), 223 (3.87), 325 (4.03), 476 (3.78) nm; IR (ATR) υmax 3347.9, 2943.4, 2831.8, 1705.2, 1643.6, 1618.5, 1567.2, 1410.8, 1207.9, 1094, 1023.4 cm−1; 1H and 13C NMR (See Table 1); HRESIMS m/z 1049.4296 [M − CH4O + H]+ (calcd for C57H65N2O17+, 1049.4278).
Lomaiviticin G (2): red power; [α]25D −354 (c 0.2, CH3OH); UV (CH3OH) λmax (log ε) 205 (3.96), 237 (3.92), 274 (3.94), 326 (4.04), 476 (3.89) nm; IR (ATR) υmax 3372.8, 2941.6, 2833.4, 1619.6, 1566.4, 1485.8, 1414.9, 1333.2, 1215.5, 1107.8, 1021.3 cm−1; 1H and 13C NMR (See Table S1); HRESIMS m/z 1035.4151 [M + H]+ (calcd for C56H63N2O17+, 1035.4121).
Lomaiviticin H (3): red power; [α]25D −225 (c 0.2, CH3OH); UV (CH3OH) λmax (log ε) 207 (4.06), 226 (3.78), 320 (4.16), 477 (3.86) nm; IR (ATR) υmax 3344.2, 2943.4, 2832.8, 2140.8, 1618.9, 1567.5, 1486.7, 1453.7, 1412.7, 1335.7, 1205.1, 1095.9, 1024.8 cm−1; 1H and 13C NMR (See Table S2); HRESIMS m/z 1393.6332 [M + H]+ (calcd for C72H93N6O22+, 1393.6337).
Acid hydrolysis of (–)-Lomaiviticin F (1) to generate 4-O-methyl-l-angolosamine: According to the published procedure [2], a solution of 0.1 N H2SO4 (320 µL) was added to a stirred solution of (–)-lomaiviticin F (5.0 mg) in dioxane (445 µL) at room temperature (RT); then, the solution was heated at 50 °C for 40 min. After 40 min, the reaction was cooled down to RT, and dioxane was removed under a stream of dry argon. BaCO3 (20 mg) was added to the product to neutralize the reaction and the resulting neutralized mixture was filtered using a syringe filter to remove the insoluble salts. The water was removed under reduced pressure and the remaining residue was loaded to a benchtop C18 column. The sugar unit was purified by eluting with 100% water initially, grading to 20% CH3CN/H2O–water in one step. The optical rotation that we observed for the sugar unit was [α]25D −15 (c 0.15, H2O).
Hydrolysis of (–)-Lomaiviticin G (3) to generate N,N-dimethyl-l-pyrrolosamine TFA salt: According to the published procedure [2], 3 (5.0 mg) was dissolved in CH3OH (900 μL), and 100 mL 10% (v/v) trifluoroacetic acid was added to the stirred solution of 3 (5.0 mg) at RT. The resulting solution was stirred at RT for 3 h. The product mixture was then concentrated to dryness under a stream of dry argon. A 20 mL aliquot of water was added to the mixture, and the water solution was washed 3× with DCM. The water was removed under reduced pressure and the sugar unit was purified by eluting with 100% water initially, grading to 20% CH3CN/H2O–water in one step to afford N,N-dimethyl-l-pyrrolosamine as its trifluoroacetate salt (white solid, 0.7 mg). The optical rotation that we observed for the sugar unit was [α]25D −10 (c 0.07, H2O).
Cytotoxicity testing: Cell viability for cell lines LnCap, K562, NHDF, A549, MCF7, HCT-116, Hela was determined by the Cell Titer-Glo assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The cells were seeded into white 384-well plates (BD falcon) and allowed to attach overnight. The cells were then treated with each compound for 72 h prior to evaluation/cell assessments.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md23020065/s1, Figure S1: 1H NMR spectrum of lomaiviticin F (1; 500 MHz, CD3OD), Figure S2: 13C NMR spectrum of lomaiviticin F (1; 125 MHz, CD3OD), Figure S3: gCOSY spectrum of lomaiviticin F (1; 500 MHz, CD3OD), Figure S4: gHSQC spectrum of lomaiviticin F (1; 500 MHz, CD3OD), Figure S5: gHMBC spectrum of lomaiviticin F (1; 500 MHz, CD3OD); Figure S6: ROSEY Spectrum of lomaiviticin F (1; 500 MHz, CD3OD), Figure S7: Positive ion HRESIMS of lomaiviticin F (1), Figure S8: Positive ion ESI-MS/MS spectrum of lomaiviticin F (1), Figure S9: 1H NMR spectrum of lomaiviticin G (2; 500 MHz, CD3OD), Figure S10: 13C NMR spectrum of lomaiviticin G (2; 125 MHz, CD3OD), Figure S11: gCOSY spectrum of lomaiviticin G (2; 500 MHz, CD3OD), Figure S12: gHSQC spectrum of lomaiviticin G (2; 500 MHz, CD3OD), Figure S13: gHMBC spectrum of lomaiviticin G (2; 500 MHz, CD3OD), Figure S14: ROSEY spectrum of lomaiviticin G (2; 500 MHz, CD3OD), Figure S15. 1H NMR spectrum of 13C labeled lomaiviticin G (2; 500 MHz, CD3OD), Figure S16: 13C NMR spectrum of 13C labeled lomaiviticin G (2; 125 MHz, CD3OD), Figure S17: 1H NMR spectrum comparation between 13C labeled (top) and unlabeled (bottom) lomaiviticin G (2; 500 MHz, CD3OD), Figure S18: 13C NMR spectrum comparation between 13C labeled (top) and unlabeled (bottom) lomaiviticin G (2; 125 MHz, CD3OD), Figure S19: 13C-13C COSY spectrum of 13C labeled lomaiviticin G (2; 125 MHz, CD3OD), Figure S20: Positive ion HRESIMS of lomaiviticin G (2), Figure S21: Positive ion ESI-MS/MS spectrum of lomaiviticin G (2), Figure S22: 1H NMR spectrum of lomaiviticin H (3; 500 MHz, CD3OD), Figure S23: 13C NMR spectrum of lomaiviticin H (3; 125 MHz, CD3OD), Figure S24: gCOSY spectrum of lomaiviticin H (3; 500 MHz, CD3OD), Figure S25: gHSQC spectrum of lomaiviticin H (3; 500 MHz, CD3OD), Figure S26: gHMBC spectrum of lomaiviticin H (3; 500 MHz, CD3OD), Figure S27: ROSEY spectrum of lomaiviticin H (3; 500 MHz, CD3OD), Figure S28: Positive ion HRESIMS of lomaiviticin H (3), Figure S29: Positive ion ESI-MS/MS spectrum of lomaiviticin H (3), Figure S30: CD spectra of 13.

Author Contributions

Conceptualization, F.Z.; methodology, F.Z., D.R.B. and G.E.A.; software, F.Z.; validation, F.Z., W.W. and W.L.; formal analysis, F.Z., W.W. and W.L.; investigation, F.Z.; resources, D.R.B. and M.K.H.; data curation, F.Z. and W.W.; writing—original draft preparation, F.Z.; writing—review and editing, S.R.R. and T.S.B.; visualization, F.Z. and S.R.R.; supervision, F.Z.; project administration, F.Z.; funding acquisition, F.Z. and T.S.B. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by funding from: (i) the National Natural Science Foundation of China (No. 82273826) and the National Key Research and Development Program of China (No. 2022YFC2804300) to F.Z; (ii) NIH grants U19 AI109673 and U19 AI142720, grant R01 GM104192 to T.S.B. This study made use of the National Magnetic Resonance Facility at Madison (NMRFAM), which is supported by NIH grant P41GM103399 (NIGMS). The authors would like to acknowledge the UW-Madison Human Proteomics Program Mass Spectrometry Facility (initially funded by the Wisconsin partnership funds) for support in obtaining mass spectrometry data (FR-ICR MS) and NIH S10OD018475 for the acquisition of an ultrahigh-resolution mass spectrometer.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original data presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

Acknowledgments

We thank the Analytical Instrumentation Center (AIC) at the University of Wisconsin-Madison School of Pharmacy for the facilities to acquire spectroscopic data, especially MS data.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
IFSIsotopic Fine Structure
DSBDouble-Strand Breaks

References

  1. He, H.; Ding, W.; Bernan, V.S.; Richardson, A.D.; Ireland, C.M.; Greenstein, M.; Ellestad, G.A.; Carter, G.T. Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J. Am. Chem. Soc. 2001, 123, 5362–5363. [Google Scholar] [CrossRef] [PubMed]
  2. Woo, C.M.; Beizer, N.E.; Janso, J.E.; Herzon, S.B. Isolation of lomaiviticins C−E, transformation of lomaiviticin C to lomaiviticin A, complete structure elucidation of lomaiviticin A, and structure-activity analyses. J. Am. Chem. Soc. 2012, 134, 15285–15288. [Google Scholar] [CrossRef] [PubMed]
  3. Colis, L.C.; Woo, C.M.; Hegan, D.C.; Li, Z.; Glazer, P.M.; Herzon, S.B. The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA. Nat. Chem. 2014, 6, 504–510. [Google Scholar] [CrossRef] [PubMed]
  4. Colis, L.C.; Hegan, D.C.; Kaneko, M.; Glazer, P.M.; Herzon, S.B. Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines. J. Am. Chem. Soc. 2015, 137, 5741–5747. [Google Scholar] [CrossRef] [PubMed]
  5. Herzon, S.B. The mechanism of action of (-)-Lomaiviticin A. Acc. Chem. Res. 2017, 50, 2577–2588. [Google Scholar] [CrossRef]
  6. Kim, L.J.; Xue, M.; Li, X.; Xu, Z.; Paulson, E.; Mercado, B.; Nelson, H.M.; Herzon, S.B. Structure Revision of the Lomaiviticins. J. Am. Chem. Soc. 2021, 143, 6578–6585. [Google Scholar] [CrossRef] [PubMed]
  7. Ito, S.; Matsuya, T.; Omura, S.; Otani, M.; Nakagawa, A.; Takeshima, H.; Iwai, Y.; Ohtani, M.; Hata, T. A new antibiotic, kanamycin. J. Antibiot. 1970, 23, 315–317. [Google Scholar] [CrossRef] [PubMed]
  8. Hata, T.; Omura, S.; Iwai, Y.; Nakagawa, A.; Otani, M.; Ito, S.; Matsuya, T. A new antibiotic, kinamycin: Fermentation, isolation, purification and properties. J. Antibiot. 1971, 24, 353–359. [Google Scholar] [CrossRef] [PubMed]
  9. Omura, S.; Nakagawa, A.; Yamada, H.; Hata, T.; Furusaki, A.; Watanabe, T.A. Structures and biological properties of Kinamycin A, B, C, and D. Chem. Pharm. Bull. 1973, 21, 931–940. [Google Scholar] [CrossRef]
  10. Furusaki, A.; Matsui, M.; Watanabe, T.; Omura, S.; Nakagawa, A.; Hata, T. The Crystal and molecular structure of kinamycin C p-bromobenzoate. Isr. J. Chem. 1972, 10, 173–187. [Google Scholar] [CrossRef]
  11. Seaton, P.J.; Gould, S.J. New products related to kinamycin from Streptomyces murayamaensis. II. Structures of pre-kinamycin, keto-anhydrokinamycin, and kinamycins E and F. J. Antibiot. 1989, 42, 189–197. [Google Scholar] [CrossRef]
  12. Young, J.; Ho, S.; Ju, W.; Chang, L. FL-120A-D′, new products related to kinamycin from Streptomyces chattanoogensis subsp. taitungensis subsp. nov. II. Isolation and structure determination. J. Antibiot. 1994, 47, 681–687. [Google Scholar] [CrossRef]
  13. Isshiki, K.; Sawa, T.; Naganawa, H.; Matsuda, N.; Hattori, S.; Hamada, M.; Takeuchi, T. 3-O-isobutyrylkinamycin C and 4-deacetyl-4-O-isobutyrylkinamycin C, new antibiotics produced by a Saccharothrix species. J. Antibiot. 1989, 42, 467–469. [Google Scholar] [CrossRef] [PubMed]
  14. Gould, S.J.; Tamayo, N.; Melville, C.R.; Cone, M.C. Revised structures for the kinamycin antibiotics: 5-diazobenzo[b]fluorenes rather than benzo[b]carbazole cyanamides. J. Am. Chem Soc. 1994, 116, 2207–2208. [Google Scholar] [CrossRef]
  15. Janso, J.E.; Haltli, B.A.; Eustáquio, A.S.; Kulowski, K.; Waldman, A.J.; Zha, L.; Nakamura, H.; Bernan, V.S.; He, H.; Carter, G.T.; et al. Discovery of the lomaiviticin biosynthetic gene cluster in Salinispora pacifica. Tetrahedron 2014, 70, 4156–4164. [Google Scholar] [CrossRef] [PubMed]
  16. Kersten, R.D.; Lane, A.L.; Nett, M.; Richter, T.K.S.; Duggan, B.M.; Dorrestein, P.C.; Moore, B.S. Bioactivity-guided genome mining reveals the lomaiviticin biosynthetic gene cluster in Salinispora tropica. ChemBioChem 2013, 14, 955–962. [Google Scholar] [CrossRef]
  17. Xue, M.; Herzon, S.B. Mechanism of nucleophilic activation of (-)-lomaiviticin A. J. Am. Chem. Soc. 2016, 138, 15559–15562. [Google Scholar] [CrossRef] [PubMed]
  18. Zhang, F.; Wyche, T.P.; Zhu, Y.; Braun, D.R.; Yan, J.-X.; Chanana, S.; Ge, Y.; Guzei, I.A.; Chevrette, M.G.; Currie, C.R.; et al. MS-derived isotopic fine structure reveals forazoline A as a thioketone-containing marine-derived natural product. Org. Lett. 2020, 22, 1275–1279. [Google Scholar] [CrossRef]
  19. Yan, J.X.; Wu, Q.; Maity, M.; Braun, D.R.; Alas, I.; Wang, X.; Yin, X.; Zhu, Y.; Bell, B.A.; Rajski, S.R.; et al. Rapid unambiguous structure elucidation of streptnatamide A, a new cyclic peptide isolated from a marine-derived Streptomyces sp. Chemistry 2023, 29, e202301813. [Google Scholar] [CrossRef]
  20. Kind, T.; Fiehn, O. Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinf. 2007, 8, 105. [Google Scholar] [CrossRef] [PubMed]
  21. Jiang, X.; Zhang, Q.; Zhu, Y.; Nie, F.; Wu, Z.; Yang, C.; Zhang, L.; Tian, X.; Zhang, C. Isolation, structure elucidation and biosynthesis of benzo[b]fluorene nenestatin A from deep-sea derived Micromonospora echinospora SCSIO 04089. Tetrahedron 2017, 73, 3585–3590. [Google Scholar] [CrossRef]
  22. Jiang, X.; Fang, Z.; Zhang, Q.; Liu, W.; Zhang, L.; Zhang, W.; Yang, C.; Zhang, H.; Zhu, Y.; Zhang, C. Discovery of a new asymmetric dimer nenestatin B and implications of a dimerizing enzyme in a deep sea actinomycete. Org. Biomol. Chem. 2021, 19, 4243–4247. [Google Scholar] [CrossRef] [PubMed]
  23. Bear, H.H.; Georges, F.F.Z. The synthesis of D-angolosamine. Can. J. Chem. 1977, 55, 1100–1103. [Google Scholar] [CrossRef]
  24. Hayakawa, M.; Nonomura, H. Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J. Ferment. Technol. 1987, 65, 501–509. [Google Scholar] [CrossRef]
  25. Shirling, E.B.; Gottlieb, D. Methods for characterization of Streptomyces species. Int. J. Syst. Bacteriol. 1966, 16, 313–340. [Google Scholar] [CrossRef]
  26. Reasoner, D.J.; Geldreich, E.E. A new medium for the enumeration and subculture of bacteria from potable water. Appl. Environ. Microbiol. 1985, 49, 1–7. [Google Scholar] [CrossRef] [PubMed]
  27. Gauze, G.F.; Preobrazhenskaya, J.P.; Kudrina, E.E.; Blinov, N.O.; Ryabova, I.D.; Sveshnikova, M.A. Problems in the Classification of Antagonistic Actinomycetes; State Publishing House for Medical Literature: Moscow, Russia, 1957. [Google Scholar]
  28. Kim, B.-Y.; Kshetrimayum, J.D.; Goodfellow, M. Detection, selective isolation and characterisation of Dactylosporangium strains from diverse environmental samples. Syst. Appl. Microbiol. 2011, 34, 606–616. [Google Scholar] [CrossRef] [PubMed]
  29. Wyche, T.P.; Hou, Y.; Braun, D.; Cohen, H.C.; Xiong, M.P.; Bugni, T.S. First natural analogs of the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp. J. Org. Chem. 2011, 76, 6542–6547. [Google Scholar] [CrossRef]
Figure 1. Representative structures of lomaiviticins, kanamycin A, and nenestatins. Lomaiviticins and kinamycins contain diazofluorene functional groups (lomaiviticin A contains two diazofluorenes; lomaiviticin C and kinamycin A contain one diazofluorene), which are unique among known natural products.
Figure 1. Representative structures of lomaiviticins, kanamycin A, and nenestatins. Lomaiviticins and kinamycins contain diazofluorene functional groups (lomaiviticin A contains two diazofluorenes; lomaiviticin C and kinamycin A contain one diazofluorene), which are unique among known natural products.
Marinedrugs 23 00065 g001
Figure 2. Structures of lomaiviticins F–H (13). Lomaiviticin H (3) contains only one diazofluorene moiety, whereas lomaiviticins F and G contain none.
Figure 2. Structures of lomaiviticins F–H (13). Lomaiviticin H (3) contains only one diazofluorene moiety, whereas lomaiviticins F and G contain none.
Marinedrugs 23 00065 g002
Figure 3. IFS of lomaiviticins F–H (13). (a) FT-ICR-MS data of the crude extract sample of strain WMMC-274. (b) Comparison of IFS of compound 1 ([M + H − CH4O]+ with calculated IFS for C57H65N2O17+. (c) Comparison of IFS of compound 2 ([M + H]+) with calculated IFS for C56H63N2O17+. (d) Comparison of IFS of compound 3 ([M + H]+) with calculated IFS for C72H93N6O22+.
Figure 3. IFS of lomaiviticins F–H (13). (a) FT-ICR-MS data of the crude extract sample of strain WMMC-274. (b) Comparison of IFS of compound 1 ([M + H − CH4O]+ with calculated IFS for C57H65N2O17+. (c) Comparison of IFS of compound 2 ([M + H]+) with calculated IFS for C56H63N2O17+. (d) Comparison of IFS of compound 3 ([M + H]+) with calculated IFS for C72H93N6O22+.
Marinedrugs 23 00065 g003
Figure 4. Key ROESY correlations for 1.
Figure 4. Key ROESY correlations for 1.
Marinedrugs 23 00065 g004
Table 1. 1H and 13C NMR data for lomaiviticin F (1) (500 MHz for 1H, 125 MHz for 13C, CD3OD).
Table 1. 1H and 13C NMR data for lomaiviticin F (1) (500 MHz for 1H, 125 MHz for 13C, CD3OD).
PositionδC, Mult.δH (J in Hz)1H-1H COSYHMBC 1ROESY
1201.8, C
243.1, CH3.78, s41, 3, 4, 11b, 12, 2′4, 12, 13
385.6, C
474.6, CH4.84, s22, 3, 4a, 5a, 11b, 12-OMe 2
4-OMe59.1, CH33.51, s 4
4a128.9, C
5118.3, CH7.00, s 1, 4a, 5a, 6, 11, 11a, 11b
5a123.4, C
6184.9, C
6a118.1, C
7/10157.0, C/
156.5, C
8126.0, CH6.74, d (9.1)97, 9, 10, 6a
9125.8, CH6.58, d (9.1)87, 8, 10, 10a
10a117.1, C
11186.2, C
11a128.0, C
11b137.0, C
1230.9, CH2a: 2.25, m;
b: 2.06, m
132, 3, 132
1310.0, CH31.11, t (6.9)123, 122, 16, 18
1494.4, CH6.11, d (2.6)153, 16, 18 12b, 13
1531.0, CH2a: 2.45, m;
b: 1.82, m
14, 1614, 16, 17
1662.6, CH3.33, m15, 1715, 17, 21, 2218
1784.5, CH2.98, t (9.4)16, 1816, 18, 19, 20 15b, 19, 20, 21, 22
1869.8, CH4.10, dt (6.2, 9.4)17, 1916, 17, 1916
1919.6, CH31.33 d (6.2)1817, 1817, 20
2060.4, CH33.56, s 1715a, 17, 19
2141.2, CH32.44, s 16, 2216, 17, 20
2241.2, CH32.44, s 16, 2116, 17, 20
1 HMBC correlations are from proton(s) to the indicated carbon.
Table 2. 1H, 13C and 2D NMR data for 2 (500 MHz for 1H, 125 MHz for 13C, CD3OD).
Table 2. 1H, 13C and 2D NMR data for 2 (500 MHz for 1H, 125 MHz for 13C, CD3OD).
PositionδC, Mult.δH (J in Hz)1H-1H COSYHMBC 1ROESY13C-13C COSY
1200.9, C 3, 4a
244.4, CH3.51, m4, 2′ 134, 2′
384.6, C 2, 12
425.7, CH2a: 3.36, m;
b: 2.80, m
23, 11b, 2′ 2, 11b
4a129.4, C 1
5120.1, CH6.75, s 4a, 5a, 11a, 11b
5a121.0, C 6
6184.8, C 5a, 6a
6a118.1, C 6, 7
7/10157.2, C/
157.0, C
8126.3, CH6.83, d (9.1)97, 10, 6a 7
9125.7, CH6.72, d (9.1)87, 10, 10a 10
10a117.4, C 10
11185.1, C 11a
11a127.3, C 11
11b142.7, C 1
1227.4, CH21.98, m; 1.81, m13 13
139.8, CH31.14, t (7.3)123, 121b, 2, 1412
1494.1, CH6.00, br s153, 16, 18 1315
1531.6, CH2a: 2.69, m;
b: 1.79, m
14, 16 14, 16
1662.7, CH3.44, m15, 17 18
1783.6, CH3.05, t (10.2)16, 1816, 18, 19, 20 15b, 19, 21, 2218
1869.9, CH4.04, dt (6.0, 10.2)17, 19171617, 19
1919.4, CH31.30 d (6.0)1817, 1817, 2018
2059.8, CH33.52, s 1719
2140.9, CH32.51, s 16, 2217, 20
2240.9, CH32.51, s 16, 2117, 20
1′200.9, C 3′, 4a′
2′59.0, CH4.11, d (2.4) 1′, 3′, 4′, 11b′13′2, 4′
3′85.0, C 2′, 12′
4′197.0, C 2′, 11b′
4a′132.7, C 1′
5′118.2, CH7.00, s 4′, 4a′, 5a′, 11b′
5a′122.3, C 6′
6′185.4, C 5a′
6a′117.5, C 7′
7′/10′158.1, C/
157.3, C
8′127.8, CH6.95, d (9.1) 7′, 10′, 6a′ 7′
9′127.4, CH6.90, d (9.1) 7′, 10′, 10a′ 10′
10a′115.7, C 10′, 11′
11′186.9, C 10a′, 11a′
11a′131.5, C 11′
11b′131.0, C 4′
12′30.3, CH2a: 2.00, m;
b: 1.79, m
13′2′, 3′, 13′ 3′, 13′
13′9.67, CH31.03, t (7.3)12′3′, 12′2′, 14′12′
14′94.0, CH5.98, br s15′3′, 16′, 18′13′15′
15′30.9, CH22.45, m; 1.82, m14′, 16′ 14′, 16′
16′62.7, CH3.26, m15′, 17′ 18′
17′83.6, CH3.01, t (10.5)16′, 18′16′, 18′, 19′, 20′15b′, 19′, 21′, 22′18′
18′69.8, CH4.00, dt (10.5, 6.1)17′, 19′17′16′17′, 19′
19′19.3, CH31.29 d (6.1)18′17′, 18′17′, 20′18′
20′59.8, CH33.52, s 17′19′19′
21′40.5, CH32.44, s 16′, 22′17′, 20′
22′40.5, CH32.44, s 16′, 21′17′, 20′
1 HMBC correlations are from proton(s) to the indicated carbon.
Table 3. 1H, 13C and 2D NMR data for 3 (500 MHz for 1H, 125 MHz for 13C, CD3OD).
Table 3. 1H, 13C and 2D NMR data for 3 (500 MHz for 1H, 125 MHz for 13C, CD3OD).
PositionδC, Mult.δH (J in Hz)1H-1H COSYHMBC 1ROESY
1201.8, C
243.1, CH3.78, s41, 3, 4, 11b, 12, 2′4, 12, 13
385.6, C
474.6, CH4.84, s22, 3, 4a, 5a, 11b, 12-OMe 2, 23
4a128.9, C
5118.3, CH7.00, s 1, 4a, 5a, 6, 11, 11a, 11b
5a123.4, C
6184.9, C
6a118.1, C
7/10157.0, C/
156.5, C
8126.0, CH6.74, d (9.1)97, 9, 10, 6a
9125.8, CH6.58, d (9.1)87, 8, 10, 10a
10a117.1, C
11186.2, C
11a128.0, C
11b137.0, C
1230.9, CH2a: 2.25, m;
b: 2.06, m
132, 3, 132
1310.0, CH31.11, t (6.9)123, 122, 16, 18
1494.4, CH6.11, d (2.6)153, 16, 18 12b, 13
1531.0, CH2a: 2.45, m;
b: 1.82, m
14, 1614, 16, 17
1662.6, CH3.33, m15, 1715, 17, 21, 2218
1784.5, CH2.98, t (9.4)16, 1816, 18, 19, 20 15b, 19, 20, 21, 22
1869.8, CH4.10, dt (6.2, 9.4)17, 1916, 17, 1916
1919.6, CH31.33 d (6.2)1817, 1817, 20
2060.4, CH33.56, s 1715a, 17, 19
2141.2, CH32.44, s 16, 2216, 17, 20
2241.2, CH32.44, s 16, 2116, 17, 20
1′201.8, C
2′43.1, CH3.78, s4′1′, 3′, 4′, 11b′, 12′, 24′, 12′, 13′
3′85.6, C
4′74.6, CH4.84, s2′2′, 3′, 4a′, 5a′, 11b′, 12′-OMe 2′, 23′
4a′128.9, C
5′118.3, CH7.00, s 1′, 4a′, 5a′, 6′, 11′, 11b′
5a′123.4, C
6′184.9, C
6a′118.1, C
7′/10′157.0, C/
156.5, C
8′126.0, CH6.74, d (9.1)9′7′, 9′, 10′, 6a′
9′125.8, CH6.58, d (9.1)8′7′, 8′, 10′, 10a′
10a′117.1, C
11′186.2, C
11a′128.0, C
11b′137.0, C
12′30.9, CH22.25, m; 2.06, m13′2′, 3′, 13′2′
13′10.0, CH31.11, t (6.9)12′3′, 12′2′, 16′, 18′
14′94.4, CH6.11, d (2.6)15′3′, 16′, 18′12b′, 13′
15′31.0, CH22.45, m; 1.82, m14′, 16′14′, 16′, 17′
16′62.6, CH3.33, m15′, 17′15′, 17′, 21′, 22′18′
17′84.5, CH2.98, m16′, 18′16′, 18′, 19′, 20′15b′, 19′, 20′, 21′, 22′
18′69.8, CH4.10, m17′, 19′16′, 17′, 19′16′
19′19.6, CH31.33 d (6.2)18′17′, 18′17′, 20′
20′60.4, CH33.56, s 17′15a′, 17′, 19′
21′41.2, CH32.44, s 16′, 22′16′, 17′, 20′
22′41.2, CH32.44, s 16′, 21′16′, 17′, 20′
1 HMBC correlations are from proton(s) to the indicated carbon.
Table 4. IC50 values (µM) of lomaiviticins F–H (13) against cancer cell lines.
Table 4. IC50 values (µM) of lomaiviticins F–H (13) against cancer cell lines.
Cell Lines123
LNCaP>20>20>20
K562>205.75>20
NHDF>20>20>20
A5499.48.3412
MCF75.4>20>20
HCT-116>20>209.79
HeLa11.110.613.1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhang, F.; Wang, W.; Braun, D.R.; Ananiev, G.E.; Liao, W.; Harper, M.K.; Rajski, S.R.; Bugni, T.S. Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium. Mar. Drugs 2025, 23, 65. https://doi.org/10.3390/md23020065

AMA Style

Zhang F, Wang W, Braun DR, Ananiev GE, Liao W, Harper MK, Rajski SR, Bugni TS. Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium. Marine Drugs. 2025; 23(2):65. https://doi.org/10.3390/md23020065

Chicago/Turabian Style

Zhang, Fan, Wenhui Wang, Doug R. Braun, Gene E. Ananiev, Weiting Liao, Mary Kay Harper, Scott R. Rajski, and Tim S. Bugni. 2025. "Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium" Marine Drugs 23, no. 2: 65. https://doi.org/10.3390/md23020065

APA Style

Zhang, F., Wang, W., Braun, D. R., Ananiev, G. E., Liao, W., Harper, M. K., Rajski, S. R., & Bugni, T. S. (2025). Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium. Marine Drugs, 23(2), 65. https://doi.org/10.3390/md23020065

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop